ライフサイエンスコーパス: biological agent

1 t could be wrought by a terrorist's use of a biological agent.

2 n ideal target for site-specific delivery of biological agents.

3 orally active small molecule alternatives to biological agents.

4 es limits the therapeutic potential of these biological agents.

5 hn's disease, there are few clinical data on biological agents.

6 are not appreciably degraded by a variety of biological agents.

7 ession of these changes could be produced by biological agents.

8 ologies and may complement current anti-VEGF biological agents.

9 tribution against a robust database of known biological agents.

10 ling to consider as vehicles for delivery of biological agents.

11 signaling pathways with small molecules and biological agents.

12 trating, processing and sensing chemical and biological agents.

13 ions and high costs restrict prescription of biological agents.

14 e enough to be compatible with sophisticated biological agents.

15 tifying and managing casualties from various biological agents.

16 ombining anti-VEGF therapy with cytotoxic or biological agents.

17 d supplementation, herbal products and other biological agents, acupuncture, massage, exercise, and p

18 ated as low risk of bias and showed that all biological agents (adalimumab, golimumab, infliximab, an

19 re cystectomy and consolidation therapy with biological agents after first-line therapy provide a fra

20 The development of neutralising biological agents against TNF-alpha has allowed us to te

21 In parallel with the development of several 'biological' agents, alternative therapeutic options have

22 Dependent on the biological agent and contaminated food, such an outbreak

23 d that human stool should be classified as a biological agent and its use should be regulated to ensu

24 New therapeutic approaches, such as biological agents and mycophenolate mofetil, will also b

25 Disease-modifying biological agents and other drug regimens have substanti

26 of adverse events was not different between biological agents and placebo.

27 Exposure to multiple biological agents and risk of reporting eczema, allergy

28 nt as well as possible new insulin-releasing biological agents and small-molecule inhibitors of gluca

29 New biological agents and somatostatin-tagged radionuclides

30 nitor the location and transfer of hazardous biological agents and to insure that any use of such age

31 omise include intravenous immunoglobulin and biological agents and trials of the newest treatments ar

32 r involvement of the liver, planned use of a biological agent, and investigational centre.

33 -2 in vivo for use in combination with other biological agents, and for studies of its antitumor acti

34 es have yet to be undertaken for these novel biological agents, and it is unclear whether any of thes

35 options have expanded with the advent of the biological agents, and these may yet improve outcomes, p

36 o selectively engineer the NP, to colocalize biological agents, and to enhance the stability of those

37 particularly steroids, immunomodulators, and biological agents; and a high risk of recurrence.

38 Biological agents are effective treatments for UC, but h

39 Biological agents are emerging treatment options for the

40 In the West, biological agents are the fastest-growing segment of the

41 Biological agents are the most complex systems humans ha

42 As newer biological agents are translated from the lab to the bed

43 Biological agents are used when arthritis is uncontrolle

44 In particular, the use of biological agents as radiosensitizers has led to the inv

45 The modern development of biological agents as weapons has paralleled advances in

46 Concern regarding the use of biological agents--bacteria, viruses, or toxins--as tool

47 oday are complacent about the possibility of biological agents being intentionally used to cause wide

48 2004) for articles relating to bioterrorism, biological agents, biological warfare, hospital prepared

49 idually targeted therapies such as the newer biological agents, but how successful this approach will

50 onventional therapy is commonly scaled up to biological agents, but surgery can also offer excellent

51 n be protected against potentially hazardous biological agents by using engineering controls, good la

52 volumes, the cell microenvironment and other biological agents can be bioengineered; interactions bet

53 ention has been paid to scenarios in which a biological agent capable of person-to-person transmissio

54 All biological agents currently used for reducing TNFalpha a

55 able instruments for environmental analysis, biological agent detection, or diagnostics.

56 nostics, environmental testing and defensive biological agent detection.

57 ination procedures, the role of chemical and biological agent detectors, and potential environmental

58 muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in

59 Biological agents directed against the interleukin-13 pa

60 een reported in humans treated with anti-TNF biological agents, disparate rates of disease have been

61 The significant threat posed by biological agents (e.g. anthrax, tetanus, botulinum, and

62 ulin E and tumour necrosis factor alpha with biological agents, emphasise the need for careful phenot

63 cacy of a combination of methotrexate with a biological agent, especially a tumor-necrosis-factor blo

64 ation proposes methodologies for recovery of biological agent followed by an off-site unambiguous det

65 ur necrosis factor inhibitors were the first biological agents, followed by abatacept, rituximab, and

66 in the process of developing or acquiring a biological agent for use as a weapon.

67 Weaponization of biological agents for aerosol dispersal is difficult and

68 ocesses have led to the development of novel biological agents for the treatment of chronic inflammat

69 The development of biological agents for the treatment of solid tumours is

70 Introduction of biological agents for the treatment of the chronic infla

71 form of therapy for many patients, an era of biological agents for therapy in inflammatory bowel dise

72 Accidental release of biological agents from a bioweapon facility may contamin

73 The release of biological agents from conventional porous scaffolds is

74 For more than a decade, a biological agent has been suspected to cause free-branch

75 Deliberate contamination of food with biological agents has already been perpetrated in the US

76 Biological agents have been used as instruments of warfa

77 Biological agents have dramatically improved treatment o

78 were rated high risk of bias showed that all biological agents have greater clinical efficacy than pl

79 he site of exposure, diseases resulting from biological agents have incubation periods of days.

80 uld be carefully assessed when investigating biological agents in combination and should never be don

81 The integration of these new biological agents in combination with chemotherapy, in o

82 es provide new tools to manipulate cells and biological agents in micro/nano-liter volumes.

83 ficacy of novel immunologic approaches using biological agents in patients with AD is available for t

84 These two fungal species were used as biological agents in Poland to control Melolontha melolo

85 Viruses are the most common biological agents in the sea, typically numbering ten bi

86 The role of biological agents in the treatment of this common, yet c

87 MSCs may serve as a platform for delivery of biological agents in tumors.

88 body temperatures in vitro but are effective biological agents in vivo.

89 of intensity modulated radiation therapy and biological agents into CRT treatment approaches may redu

90 ell cancer, particularly the introduction of biological agents into treatment paradigms, and some of

91 olved in a plethora of cellular responses to biological agents involving activation of adenylyl cycla

92 products (SMNPs) in the discovery of active biological agents is discussed.

93 bel-free and direct detection of aerosolized biological agents is presented here.

94 ovocation test (DPT) with antineoplastic and biological agents is scarce.

95 care and with technological breakthroughs in biological agents, is giving new hope to the problem of

96 Published work suggests that biological agents, like traditional treatments, have the

97 ed mesenchymal stem cells (MSCs) can produce biological agents locally at tumor sites.

98 invisible, silent, odorless, and tasteless, biological agents may be used as an ultimate weapon-easy

99 der the importance of two neutrophil-derived biological agents: neutrophil extracellular traps and ec

100 molecular biology and the emergence of novel biological agents now offer the possibility of improved

101 Viruses are key biological agents of prokaryotic mortality in the world

102 Biological agents offer good control of rheumatoid arthr

103 olled by a magnetic field to deliver various biological agents on demand.

104 imes, hoaxes, or the accidental release of a biological agent or toxin for attribution purposes.

105 Immunotherapy with biological agents or small molecules is revolutionising

106 , showcasing the effective "activation" of a biological agent otherwise inactive within the investiga

107 However, the incremental benefit of these biological agents over less expensive standard wound car

108 n more than 100 DPTs with antineoplastic and biological agents (paclitaxel, oxaliplatin, rituximab, i

109 its of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone

110 ildren and adults exposed to more than eight biological agents present in the home were at reduced ri

111 Among 9 RCTs evaluating biological agents, several trials reported benefits with

112 The addition of newer biological agents (strategy C) significantly decreased t

113 The addition of newer biological agents (strategy C) significantly decreased t

114 ctor-beta-directed therapies and other novel biological agents such as hyperimmune caprine serum are

115 Further trials are needed for biological agents such as infliximab, rituximab and intr

116 uding topical intranasal corticosteroids and biological agents, such as anti-IL-5 and anti-IgE mAb, a

117 ved to be less specific than perturbation by biological agents, such as antibody and small inference

118 Finally, we show that biological agents, such as oxidized 1-palmitoyl-2-arachi

119 Recent advances in the use of biological agents, such as rituximab, have also allowed

120 Clinical investigations of novel drugs and biological agents targeting mechanisms involving CD4 typ

121 ed studies confirm that the long-term use of biological agents targeting TNF-alpha in therapy for rhe

122 Biological agents that block key T-cell costimulatory si

123 Biological agents that block T-cell costimulatory pathwa

124 n be achieved in up to 50% of patients using biological agents that inhibit tumor necrosis factor (TN

125 We investigated biological agents that might enable this.

126 eness were primary reasons for discontinuing biological agents, the inability to obtain adequate insu

127 t of rheumatoid arthritis with the advent of biological agents, the mechanisms that drive cytokine pr

128 and the external environment and chemical or biological agents therein is the olfactory epithelium (O

129 protein, lysozyme (Lys), was selected as the biological agent to be immobilized.

130 potential inhibitors of the binding of such biological agents to cell membranes has increased.

131 icrobes and are therefore being developed as biological agents to control plant diseases.

132 edge of patient phenotypes and endotypes and biological agents to target specific classes of asthma e

133 e useful for preexposure prophylaxis against biological agents used as weapons of terror, such as Bac

134 l factors affecting AD development and novel biological agents used in the treatment of AD.

135 few efforts in defining a role for the newer biological agents useful in rheumatoid arthritis and oth

136 0 bombs and 25 ballistic missiles laden with biological agents were deployed by the time Operation De

137 Biological agents were used in 45 episodes, the most com

138 motherapy, oral agents, and newer injectable biological agents, which have revolutionised the managem

139 uency shifts indicated presence of the model biological agent with limit of detection of 1.45 x 10(4)

140 The combination of probiotics, vitamins, and biological agents with AIT is highlighting current advan